within Pharmacolibrary.Drugs.C_CardiovascularSystem.C08C_SelectiveCalciumChannelBlockersWithMainlyVascula.C08CA13_Lercanidipine;

model Lercanidipine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.1,
    Cl = 1.9444444444444442e-05,
    adminDuration = 600,
    adminMass = 10 / 1000000,
    adminCount = 1,
    Vd = 0.0025,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.030000000000000002,
    Tlag = 15.0,
    Vdp = 0.018,
    k12 = 5.638888888888888e-05,
    k21 = 5.638888888888888e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Lercanidipine</td></tr><tr><td>ATC code:</td><td>C08CA13</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>10</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>2.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.0</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Lercanidipine is a dihydropyridine calcium channel blocker used for the management of mild to moderate essential hypertension. It is approved and widely used orally as an antihypertensive agent due to its long duration of action and reduced incidence of adverse effects compared to older calcium antagonists.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after oral administration in fasting conditions.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C08CA13 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Lercanidipine;
